Secondary analysis of VESALIUS-CV: in 6,002 patients with high-risk diabetes and no prior MI or stroke, evolocumab vs placebo reduced 3-point MACE (HR 0.71) and 4-point MACE (HR 0.79) over median 4.6 years; all-cause death 8.8% vs 11.0%.
Secondary analysisn = 6,002
Leiter et al. Evolocumab in Patients With High-Risk Diabetes: Results From the VESALIUS-CV Trial